vs
MITEK SYSTEMS INC（MITK）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是MITEK SYSTEMS INC的1.5倍（$65.1M vs $44.2M），MITEK SYSTEMS INC净利率更高（6.3% vs 5.6%，领先0.7%），MITEK SYSTEMS INC同比增速更快（18.8% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $6.6M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -2.9%）
MITEK SYSTEMS INC是一家专注于数字身份验证与人工智能移动图像处理领域的软件企业。其软件可支持用户通过移动设备完成支票存兑与银行账户开户，还可通过分析持证人自拍照、比对人脸与证件照，完成护照、身份证、驾照等各类身份证件的身份验证。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
MITK vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.5倍
$44.2M
营收增速更快
MITK
高出15.1%
3.6%
净利率更高
MITK
高出0.7%
5.6%
自由现金流更多
MLAB
多$11.4M
$6.6M
两年增速更快
MLAB
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $44.2M | $65.1M |
| 净利润 | $2.8M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 12.3% | 12.2% |
| 净利率 | 6.3% | 5.6% |
| 营收同比 | 18.8% | 3.6% |
| 净利润同比 | 160.1% | 316.6% |
| 每股收益（稀释后） | $0.06 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MITKMLAB
| Q4 25 | $44.2M | $65.1M | ||
| Q3 25 | $44.8M | $60.7M | ||
| Q2 25 | $45.7M | $59.5M | ||
| Q1 25 | $51.9M | $62.1M | ||
| Q4 24 | $37.3M | $62.8M | ||
| Q3 24 | $43.2M | $57.8M | ||
| Q2 24 | $45.0M | $58.2M | ||
| Q1 24 | $47.0M | $58.9M |
净利润MITKMLAB
| Q4 25 | $2.8M | $3.6M | ||
| Q3 25 | $1.9M | $2.5M | ||
| Q2 25 | $2.4M | $4.7M | ||
| Q1 25 | $9.2M | $-7.1M | ||
| Q4 24 | $-4.6M | $-1.7M | ||
| Q3 24 | $8.6M | $3.4M | ||
| Q2 24 | $216.0K | $3.4M | ||
| Q1 24 | $282.0K | $-254.6M |
毛利率MITKMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率MITKMLAB
| Q4 25 | 12.3% | 12.2% | ||
| Q3 25 | 10.5% | 7.8% | ||
| Q2 25 | 8.3% | 5.1% | ||
| Q1 25 | 21.9% | 2.4% | ||
| Q4 24 | -8.3% | 9.2% | ||
| Q3 24 | 17.8% | 6.1% | ||
| Q2 24 | 1.6% | 9.6% | ||
| Q1 24 | 1.5% | -460.6% |
净利率MITKMLAB
| Q4 25 | 6.3% | 5.6% | ||
| Q3 25 | 4.2% | 4.1% | ||
| Q2 25 | 5.2% | 8.0% | ||
| Q1 25 | 17.6% | -11.4% | ||
| Q4 24 | -12.4% | -2.7% | ||
| Q3 24 | 19.8% | 5.9% | ||
| Q2 24 | 0.5% | 5.8% | ||
| Q1 24 | 0.6% | -432.2% |
每股收益（稀释后）MITKMLAB
| Q4 25 | $0.06 | $0.65 | ||
| Q3 25 | $0.04 | $0.45 | ||
| Q2 25 | $0.05 | $0.85 | ||
| Q1 25 | $0.20 | $-1.30 | ||
| Q4 24 | $-0.10 | $-0.31 | ||
| Q3 24 | $0.19 | $0.63 | ||
| Q2 24 | $0.00 | $0.62 | ||
| Q1 24 | $0.01 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $190.1M | $29.0M |
| 总债务越低越好 | $4.8M | $68.4M |
| 股东权益账面价值 | $233.7M | $186.7M |
| 总资产 | $446.5M | $434.8M |
| 负债/权益比越低杠杆越低 | 0.02× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资MITKMLAB
| Q4 25 | $190.1M | $29.0M | ||
| Q3 25 | $193.0M | $20.4M | ||
| Q2 25 | $167.1M | $21.3M | ||
| Q1 25 | $136.2M | $27.3M | ||
| Q4 24 | $121.2M | $27.3M | ||
| Q3 24 | $130.3M | $24.3M | ||
| Q2 24 | $123.1M | $28.5M | ||
| Q1 24 | $123.9M | $28.2M |
总债务MITKMLAB
| Q4 25 | $4.8M | $68.4M | ||
| Q3 25 | $4.3M | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | $2.7M | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益MITKMLAB
| Q4 25 | $233.7M | $186.7M | ||
| Q3 25 | $240.3M | $178.5M | ||
| Q2 25 | $237.6M | $172.5M | ||
| Q1 25 | $220.2M | $159.8M | ||
| Q4 24 | $200.9M | $155.2M | ||
| Q3 24 | $214.8M | $161.5M | ||
| Q2 24 | $209.6M | $150.7M | ||
| Q1 24 | $216.1M | $145.4M |
总资产MITKMLAB
| Q4 25 | $446.5M | $434.8M | ||
| Q3 25 | $459.1M | $430.4M | ||
| Q2 25 | $446.7M | $435.7M | ||
| Q1 25 | $425.3M | $433.3M | ||
| Q4 24 | $396.0M | $433.3M | ||
| Q3 24 | $413.8M | $454.1M | ||
| Q2 24 | $409.2M | $440.4M | ||
| Q1 24 | $417.0M | $446.8M |
负债/权益比MITKMLAB
| Q4 25 | 0.02× | 0.37× | ||
| Q3 25 | 0.02× | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | 0.01× | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.0M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $6.6M | $18.0M |
| 自由现金流率自由现金流/营收 | 14.9% | 27.7% |
| 资本支出强度资本支出/营收 | 3.2% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.89× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $60.5M | $37.9M |
8季度趋势，按日历期对齐
经营现金流MITKMLAB
| Q4 25 | $8.0M | $18.8M | ||
| Q3 25 | $19.5M | $8.2M | ||
| Q2 25 | $21.6M | $1.9M | ||
| Q1 25 | $13.7M | $12.7M | ||
| Q4 24 | $565.0K | $18.1M | ||
| Q3 24 | $21.1M | $5.3M | ||
| Q2 24 | $13.0M | $10.7M | ||
| Q1 24 | $7.1M | $12.9M |
自由现金流MITKMLAB
| Q4 25 | $6.6M | $18.0M | ||
| Q3 25 | $19.2M | $7.1M | ||
| Q2 25 | $21.2M | $884.0K | ||
| Q1 25 | $13.5M | $11.9M | ||
| Q4 24 | $230.0K | $17.3M | ||
| Q3 24 | $20.8M | $3.5M | ||
| Q2 24 | $12.6M | $9.9M | ||
| Q1 24 | $6.6M | $12.3M |
自由现金流率MITKMLAB
| Q4 25 | 14.9% | 27.7% | ||
| Q3 25 | 42.9% | 11.7% | ||
| Q2 25 | 46.5% | 1.5% | ||
| Q1 25 | 26.0% | 19.2% | ||
| Q4 24 | 0.6% | 27.6% | ||
| Q3 24 | 48.2% | 6.0% | ||
| Q2 24 | 27.9% | 16.9% | ||
| Q1 24 | 14.0% | 21.0% |
资本支出强度MITKMLAB
| Q4 25 | 3.2% | 1.1% | ||
| Q3 25 | 0.6% | 1.8% | ||
| Q2 25 | 0.7% | 1.7% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 0.9% | 1.3% | ||
| Q3 24 | 0.7% | 3.1% | ||
| Q2 24 | 1.0% | 1.5% | ||
| Q1 24 | 1.0% | 0.9% |
现金转化率MITKMLAB
| Q4 25 | 2.89× | 5.17× | ||
| Q3 25 | 10.46× | 3.32× | ||
| Q2 25 | 9.00× | 0.40× | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.46× | 1.54× | ||
| Q2 24 | 60.12× | 3.17× | ||
| Q1 24 | 25.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MITK
| Fraud And Identity Solutions | $25.5M | 58% |
| License | $13.9M | 31% |
| Fraud And Identity Solutions Software License And Support | $3.9M | 9% |
| Professional Services And Other | $1.2M | 3% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
